Havemann-Reinecke, Ursula

[["dc.bibliographiccitation.firstpage","67"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","PSYCHOPHARMAKOTHERAPIE"],["dc.bibliographiccitation.lastpage","74"],["dc.bibliographiccitation.volume","15"],["dc.contributor.author","Ulrich, Sven"],["dc.contributor.author","Laux, Gerd"],["dc.contributor.author","Moller-Oerlinghausen, Bruno"],["dc.contributor.author","Havemann-Reinecke, Ursula"],["dc.contributor.author","Riederer, Peter"],["dc.contributor.author","Zernig, Gerald"],["dc.contributor.author","Baumann, Pierre"],["dc.contributor.author","Lausanne, Prilly"],["dc.contributor.author","Hiemke, Christoph"],["dc.date.accessioned","2018-11-07T11:18:02Z"],["dc.date.available","2018-11-07T11:18:02Z"],["dc.date.issued","2008"],["dc.description.abstract","Therapeutic drug monitoring (TDM) of psycho-pharmaceuticals is the practical therapeutic application of pharmacokinetic principles in pharmacopsychiatry. The prescription information (summary of product characteristics, SPC) is provided by pharmaceutical companies according to requirements of regulatory authorities and determines the framework of clinical application of a drug. The present study investigated the degree of agreement of German SPCs for 48 psychopharmaceuticals with the existing medico-scientific evidence in the area of TDM. For this aim, an empirical summary score of SPC-content related to TDM (SPCCTDM) was calculated and compared with the level of recommendation of TDM (LOR) of the AGNP-TDM expert group consensus guidelines. Considerable disagreement was found between the information on TDM in SPCs and existing medico-scientific evidence, e. g. in case of antidepressant and antipsychotic drugs. No correlation was found between SPCCTDM and LOR. Even for well studied compounds in TDM such as amitriptyline and clozapine, insufficient information on TDM is included in German SPCs. Generally, it must be concluded that deficits exist in the preparation of German SPCs of psychopharmaceutical drugs with respect to empirical pharmacokinetic data, i.e. TDM-relevant information. It is recommended that SPCs of psychopharmaceuticals should be improved in terms of TDM-related information and that target plasma concentrations have to be adjusted according to the guidelines of the AGNP-TDM expert group. A higher level of good pharmacokinetic practice may be thus achieved."],["dc.identifier.isi","000254795300006"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/54953"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wissenschaftliche Verlag Mbh"],["dc.relation.issn","0944-6877"],["dc.title","Value and actuality of the prescription information for therapeutic drug monitoring of psychopharmaceuticals: a comparison with the medico-scientific evidence"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","The International Journal of Neuropsychopharmacology"],["dc.bibliographiccitation.volume","7"],["dc.contributor.author","Rygula, Rafal"],["dc.contributor.author","Flugge, G."],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Hiemke, Christoph"],["dc.contributor.author","Havemann-Reinecke, Ursula"],["dc.date.accessioned","2018-11-07T10:48:30Z"],["dc.date.available","2018-11-07T10:48:30Z"],["dc.date.issued","2004"],["dc.format.extent","S458"],["dc.identifier.isi","000224663002518"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/48208"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Cambridge Univ Press"],["dc.publisher.place","New york"],["dc.relation.conference","24th CINP Congress"],["dc.relation.eventlocation","Paris, FRANCE"],["dc.relation.issn","1461-1457"],["dc.title","Chronic psychosocial stress in rats as a model of depression - Behavioral and pharmacological studies"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","European Psychiatry"],["dc.bibliographiccitation.volume","27"],["dc.contributor.author","Havemann-Reinecke, Ursula"],["dc.contributor.author","Bruenen, Sonja"],["dc.contributor.author","Vincent, Philippe D."],["dc.contributor.author","Baumann, P."],["dc.contributor.author","Hiemke, Christoph"],["dc.date.accessioned","2018-11-07T09:15:08Z"],["dc.date.available","2018-11-07T09:15:08Z"],["dc.date.issued","2012"],["dc.identifier.isi","000306695400169"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/27605"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier France-editions Scientifiques Medicales Elsevier"],["dc.publisher.place","Paris"],["dc.relation.issn","0924-9338"],["dc.title","TDM IN PATIENTS WITH SUBSTANCE RELATED DISORDERS"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","162"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","The World Journal of Biological Psychiatry"],["dc.bibliographiccitation.lastpage","174"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Schoretsanitis, Georgios"],["dc.contributor.author","Paulzen, Michael"],["dc.contributor.author","Unterecker, Stefan"],["dc.contributor.author","Schwarz, Markus"],["dc.contributor.author","Conca, Andreas"],["dc.contributor.author","Zernig, Gerald"],["dc.contributor.author","Gründer, Gerhard"],["dc.contributor.author","Haen, Ekkerhard"],["dc.contributor.author","Baumann, Pierre"],["dc.contributor.author","Bergemann, Niels"],["dc.contributor.author","Clement, Hans Willi"],["dc.contributor.author","Domschke, Katharina"],["dc.contributor.author","Eckermann, Gabriel"],["dc.contributor.author","Egberts, Karin"],["dc.contributor.author","Gerlach, Manfred"],["dc.contributor.author","Greiner, Christine"],["dc.contributor.author","Havemann-Reinecke, Ursula"],["dc.contributor.author","Hefner, Gudrun"],["dc.contributor.author","Helmer, Renate"],["dc.contributor.author","Janssen, Ger"],["dc.contributor.author","Jaquenoud-Sirot, Eveline"],["dc.contributor.author","Laux, Gerd"],["dc.contributor.author","Messer, Thomas"],["dc.contributor.author","Mössner, Rainald"],["dc.contributor.author","Müller, Matthias J."],["dc.contributor.author","Pfuhlmann, Bruno"],["dc.contributor.author","Riederer, Peter"],["dc.contributor.author","Saria, Alois"],["dc.contributor.author","Schoppek, Bernd"],["dc.contributor.author","Silva Gracia, Margarete"],["dc.contributor.author","Stegmann, Benedikt"],["dc.contributor.author","Steimer, Werner"],["dc.contributor.author","Stingl, Julia C."],["dc.contributor.author","Uhr, Manfred"],["dc.contributor.author","Ulrich, Sven"],["dc.contributor.author","Waschgler, Roland"],["dc.contributor.author","Zurek, Gabriela"],["dc.contributor.author","Hiemke, Christoph"],["dc.date.accessioned","2020-12-10T18:15:20Z"],["dc.date.available","2020-12-10T18:15:20Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1080/15622975.2018.1439595"],["dc.identifier.eissn","1814-1412"],["dc.identifier.issn","1562-2975"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/74812"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","195"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Pharmacopsychiatry"],["dc.bibliographiccitation.lastpage","235"],["dc.bibliographiccitation.volume","44"],["dc.contributor.author","Hiemke, Christoph"],["dc.contributor.author","Baumann, P."],["dc.contributor.author","Bergemann, N."],["dc.contributor.author","Conca, A."],["dc.contributor.author","Dietmaier, O."],["dc.contributor.author","Egberts, K."],["dc.contributor.author","Fric, M."],["dc.contributor.author","Gerlach, M."],["dc.contributor.author","Greiner, C."],["dc.contributor.author","Gruender, Gerhard"],["dc.contributor.author","Haen, E."],["dc.contributor.author","Havemann-Reinecke, Ursula"],["dc.contributor.author","Sirot, E. Jaquenoud"],["dc.contributor.author","Kirchherr, H."],["dc.contributor.author","Laux, Gerd"],["dc.contributor.author","Lutz, U. C."],["dc.contributor.author","Messer, Thomas"],["dc.contributor.author","Mueller, M. J."],["dc.contributor.author","Pfuhlmann, B."],["dc.contributor.author","Rambeck, B."],["dc.contributor.author","Riederer, Peter"],["dc.contributor.author","Schoppek, B."],["dc.contributor.author","Stingl, Julia Carolin"],["dc.contributor.author","Uhr, Manfred"],["dc.contributor.author","Ulrich, S."],["dc.contributor.author","Waschgler, R."],["dc.contributor.author","Zernig, Gerald"],["dc.date.accessioned","2018-11-07T08:51:59Z"],["dc.date.available","2018-11-07T08:51:59Z"],["dc.date.issued","2011"],["dc.description.abstract","Therapeutic drug monitoring (TDM), i.e., the quantification of serum or plasma concentrations of medications for dose optimization, has proven a valuable tool for the patient-matched psychopharmacotherapy. Uncertain drug adherence, suboptimal tolerability, non-response at therapeutic doses, or pharmacokinetic drug-drug interactions are typical situations when measurement of medication concentrations is helpful. Patient populations that may predominantly benefit from TDM in psychiatry are children, pregnant women, elderly patients, individuals with intelligence disabilities, forensic patients, patients with known or suspected genetically determined pharmacokinetic abnormalities or individuals with pharmacokinetically relevant comorbidities. However, the potential benefits of TDM for optimization of pharmacotherapy can only be obtained if the method is adequately integrated into the clinical treatment process. To promote an appropriate use of TDM, the TDM expert group of the Arbeitsgemeinschaft fur Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) issued guidelines for TDM in psychiatry in 2004. Since then, knowledge has advanced significantly, and new psychopharmacologic agents have been introduced that are also candidates for TDM. Therefore the TDM consensus guidelines were updated and extended to 128 neuropsychiatric drugs. 4 levels of recommendation for using TDM were defined ranging from \"strongly recommended\" to \"potentially useful\". Evidence-based \"therapeutic reference ranges\" and \"dose related reference ranges\" were elaborated after an extensive literature search and a structured internal review process. A \"laboratory alert level\" was introduced, i.e., a plasma level at or above which the laboratory should immediately inform the treating physician. Supportive information such as cytochrome P450 substrate and inhibitor properties of medications, normal ranges of ratios of concentrations of drug metabolite to parent drug and recommendations for the interpretative services are given. Recommendations when to combine TDM with pharmacogenetic tests are also provided. Following the guidelines will help to improve the outcomes of psychopharmacotherapy of many patients especially in case of pharmacokinetic problems. Thereby, one should never forget that TDM is an interdisciplinary task that sometimes requires the respectful discussion of apparently discrepant data so that, ultimately, the patient can profit from such a joint effort."],["dc.identifier.doi","10.1055/s-0031-1286287"],["dc.identifier.isi","000296086300154"],["dc.identifier.pmid","21969060"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/22062"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.relation.issn","0176-3679"],["dc.title","AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","561"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Therapeutic Drug Monitoring"],["dc.bibliographiccitation.lastpage","572"],["dc.bibliographiccitation.volume","33"],["dc.contributor.author","Bruenen, Sonja"],["dc.contributor.author","Vincent, Philippe D."],["dc.contributor.author","Baumann, Pierre"],["dc.contributor.author","Hiemke, Christoph"],["dc.contributor.author","Havemann-Reinecke, Ursula"],["dc.date.accessioned","2018-11-07T08:51:25Z"],["dc.date.available","2018-11-07T08:51:25Z"],["dc.date.issued","2011"],["dc.description.abstract","Background: The efficacy of drugs for the treatment of substance-related disorders is moderate at best. Therapeutic drug monitoring (TDM) could be an instrument to improve outcomes. Because TDM for most of those drugs is not established, the authors reviewed the literature and built a rating scale to detect the potential added value of TDM for these pharmacologic agents. Methods: A literature search was performed for acamprosate, bupropion, buprenorphine, clomethiazole, disulfiram, methadone, naltrexone, and varenicline. The rating scale included 22 items and was divided in five categories: efficacy, toxicity, pharmacokinetics, patient characteristics, and cost-effectiveness. Three reference substances with established TDM were similarly assessed for comparison: clozapine, lithium, and nortriptyline. The three reference substances achieved scores of 15, 12, and 14 points, respectively. Results: Drugs for treatment of substance-related disorders achieved 3 to 17 points, 17 for methadone, 11 for buprenorphine, 10 for disulfiram, also 10 for naltrexone for the indication opioid-dependence and 9 for the indication alcohol dependence as well as bupropion, 7 points for acamprosate, 6 points for clomethiazole, and 3 for varenicline. Conclusions: It is concluded that systematic evaluation of drug- and patient-related variables with the new rating scale can estimate the appropriateness of TDM. Because their rating revealed similar scores as the three reference drugs, it is proposed that TDM should be established for bupropion, buprenorphine, disulfiram or a metabolite, methadone, and naltrexone. An objective rating of drug-and patient-related characteristics could help laboratories focus their method development on the most likely drugs to require TDM along with a thorough drug use evaluation."],["dc.identifier.doi","10.1097/FTD.0b013e31822fbf7c"],["dc.identifier.isi","000295083000001"],["dc.identifier.pmid","21912330"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21929"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","0163-4356"],["dc.title","Therapeutic Drug Monitoring for Drugs Used in the Treatment of Substance-Related Disorders: Literature Review Using a Therapeutic Drug Monitoring Appropriateness Rating Scale"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","19"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Behavioural Pharmacology"],["dc.bibliographiccitation.lastpage","29"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Rygula, Rafal"],["dc.contributor.author","Abumaria, Nashat"],["dc.contributor.author","Flugge, G."],["dc.contributor.author","Hiemke, Christoph"],["dc.contributor.author","Fuchs, E."],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Havemann-Reinecke, Ursula"],["dc.date.accessioned","2018-11-07T10:20:40Z"],["dc.date.available","2018-11-07T10:20:40Z"],["dc.date.issued","2006"],["dc.description.abstract","Recently, we have described a new model of chronic social stress in rats, based on the resident-intruder paradigm. In this model, rats show behavioural changes that may be considered correlates of depressive symptoms, such as anhedonia and motivational deficits. The present study was designed for pharmacological validation of this model. Animals were socially stressed for 5 weeks and, in parallel, after the first week of stress, they were subjected to chronic (4 weeks) treatment with the antidepressant drug citalopram. The drug was administered via drinking water (30 mg/kg). The optimal dose of citalopram was determined in a pilot study. After 4 weeks of treatment, plasma levels of citalopram and its metabolite were found to be within the human therapeutic range. The effects of social stress and citalopram treatment were assessed by behavioural tests. Chronically stressed rats showed reduced locomotor and exploratory activity, reduced sucrose preference and increased immobility time in the forced swimming test. Chronic oral administration of citalopram abolished those effects and normalized behaviours related to motivation and reward sensitivity. These observations provide evidence for the predictive validity of the chronic social stress paradigm as a model of depressive symptoms in rats."],["dc.identifier.doi","10.1097/01.fbp.0000186631.53851.71"],["dc.identifier.isi","000238089900003"],["dc.identifier.pmid","16377960"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41936"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","0955-8810"],["dc.title","Citalopram counteracts depressive-like symptoms evoked by chronic social stress in rats"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","PII S0006-8993(01)03136-5"],["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.issue","1-2"],["dc.bibliographiccitation.journal","Brain Research"],["dc.bibliographiccitation.lastpage","9"],["dc.bibliographiccitation.volume","926"],["dc.contributor.author","Germeyer, S."],["dc.contributor.author","Birke, A."],["dc.contributor.author","Schmitt, U."],["dc.contributor.author","Dahmen, N."],["dc.contributor.author","Hiemke, Christoph"],["dc.contributor.author","Havemann-Reinecke, Ursula"],["dc.date.accessioned","2018-11-07T10:32:03Z"],["dc.date.available","2018-11-07T10:32:03Z"],["dc.date.issued","2002"],["dc.description.abstract","Adult Wistar rats injected with the doparnine receptor agonist apomorphine display different types of motility patterns with respect to oral stereotypes and locomotor activities. It was tested whether phenotypes exhibiting either 'sniffing' or 'non-sniffing' behaviour differed in gene structures of dopamine receptors D1 or D2. Forty-five Wistar rats of both genders were tested after a single dose of apomorphine (2 mg/kg s.c.) for stereotyped behaviour. Sequence analysis of the 5' flanking region, the 5' untranslated region and the coding region of the two genes revealed a new sequence for the 5' flanking region of the D1 receptor gene and two polymorphisms in the promoter region of the D2 receptor gene. The D2 receptor polymorphisms were denominated as T-355C- and A-257G-polymorphism. Between 'sniffing' and 'non-sniffing' animals no differences were detected in their D1 receptor sequence but there was a significant (P<0.05) association of the two phenotype groups with the D2 receptor genotype. These findings indicate that in Wistar rats at least part of an individual apomorphine stimulated behavioural phenotype might be due to an individual dopamine receptor D2 genotype. (C) 2002 Elsevier Science B.V. All rights reserved."],["dc.identifier.doi","10.1016/S0006-8993(01)03136-5"],["dc.identifier.isi","000173904000001"],["dc.identifier.pmid","11814400"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/44256"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","0006-8993"],["dc.title","New dopamine D2 receptor polymorphisms in rats and association with apomorphine-induced stereotypies"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Pharmacopsychiatry"],["dc.bibliographiccitation.volume","40"],["dc.contributor.author","Havemann-Reinecke, Ursula"],["dc.contributor.author","Brueckner, A."],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Genee, C."],["dc.contributor.author","Hiemke, Christoph"],["dc.date.accessioned","2018-11-07T10:59:20Z"],["dc.date.available","2018-11-07T10:59:20Z"],["dc.date.issued","2007"],["dc.format.extent","209"],["dc.identifier.isi","000249873600026"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50676"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.publisher.place","Stuttgart"],["dc.relation.conference","25th Symposium of the Arbeitsgemeinschaft-Neuropsychopharmakologie-und-Pharmakopsychiatrie"],["dc.relation.eventlocation","Munich, GERMANY"],["dc.relation.issn","0176-3679"],["dc.title","Factors affecting the pharmacokinetics of escitalopram - Data from a naturalistic study"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","463"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Der Nervenarzt"],["dc.bibliographiccitation.lastpage","471"],["dc.bibliographiccitation.volume","90"],["dc.contributor.author","Unterecker, Stefan"],["dc.contributor.author","Hefner, Gudrun"],["dc.contributor.author","Baumann, Pierre"],["dc.contributor.author","Gründer, Gerd"],["dc.contributor.author","Bergemann, Niels"],["dc.contributor.author","Clement, Hans-Willi"],["dc.contributor.author","Conca, Andreas"],["dc.contributor.author","Deckert, Jürgen"],["dc.contributor.author","Domschke, Katharina"],["dc.contributor.author","Eckermann, Gabriel"],["dc.contributor.author","Egberts, Karin"],["dc.contributor.author","Gerlach, Manfred"],["dc.contributor.author","Greiner, Christine"],["dc.contributor.author","Haen, Ekkehard"],["dc.contributor.author","Havemann-Reinecke, Ursula"],["dc.contributor.author","Helmer, Renate"],["dc.contributor.author","Janssen, Ger"],["dc.contributor.author","Jaquenoud, Eveline"],["dc.contributor.author","Laux, Gerd"],["dc.contributor.author","Messer, Thomas"],["dc.contributor.author","Mössner, Rainald"],["dc.contributor.author","Müller, Matthias J."],["dc.contributor.author","Paulzen, Michael"],["dc.contributor.author","Pfuhlmann, Bruno"],["dc.contributor.author","Riederer, Peter"],["dc.contributor.author","Saria, Alois"],["dc.contributor.author","Schoppek, Bernd"],["dc.contributor.author","Schoretsanitis, Georgios"],["dc.contributor.author","Schwarz, Markus"],["dc.contributor.author","Gracia, Margarethe Silva"],["dc.contributor.author","Stegmann, Benedikt"],["dc.contributor.author","Steimer, Werner"],["dc.contributor.author","Stingl, Julia C."],["dc.contributor.author","Uhr, Manfred"],["dc.contributor.author","Ulrich, Sven"],["dc.contributor.author","Waschgler, Roland"],["dc.contributor.author","Zernig, Gerald"],["dc.contributor.author","Zurek, Gabriele"],["dc.contributor.author","Hiemke, Christoph"],["dc.date.accessioned","2020-12-10T14:08:37Z"],["dc.date.available","2020-12-10T14:08:37Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1007/s00115-018-0643-9"],["dc.identifier.eissn","1433-0407"],["dc.identifier.issn","0028-2804"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70500"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-354"],["dc.relation.haserratum","/handle/2/70504"],["dc.title","Therapeutisches Drug-Monitoring in der Neuropsychopharmakologie"],["dc.title.alternative","Therapeutic drug monitoring in neuropsychopharmacology. Summary of the consensus guidelines 2017 of the TDM task force of the AGNP"],["dc.title.subtitle","Zusammenfassung der Konsensusleitlinien 2017 der TDM-Arbeitsgruppe der AGNP"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]